As we enter the second half of the year, we believe we are well positioned to deliver value across our entire portfolio of clinical-stage product candidates, including reporting topline data for the Ovaprene postcoital test clinical trial and initiating the Phase 3 study for DARE-BV1 in the fourth quarter of 2019, and continuing to advance the Sildenafil Cream, 3.6% program for Female
Sexual Arousal Disorder."
Efficacy was seen in both women with HSDD and combined HSDD/female
sexual arousal disorder (FSAD).
The influencing factors might be physiological, psychological, negative experiences in relationships, low levels of happiness and overall well-being, emotional distress, sexual desire disorders,
sexual arousal disorder, orgasmic disorder, sexual pain disorders, beliefs, past and present experiences/relationships, lifestyle, and other mood disorders (2-32).
Topical alprostadil in the treatment of female
sexual arousal disorder: a pilot study.
M2 PHARMA-September 22, 2017-Innovus Partner Luminarie Receives New Zealand Approval for Zestra for Female
Sexual Arousal Disorder as a Medical Device I
Female
sexual arousal disorder with and without a distress criterion: prevalence and correlates in a representative Czech sample.
The women had to score lower than 26 on the Female Sexual Function Index (FSFI) and lower than 11 on the Female Sexual Distress Scale (FSDS) and demonstrate one more of the following female sexual dysfunction (FSD) issues: hypoactive sexual desire disorder (HSDD), female
sexual arousal disorder (FSAD), female orgasmic disorder (FOD), or combined genital and subjective arousal disorder.
Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female
sexual arousal disorder. J Women's Health Gend Based Med 2002; 11:367-377.
Female
sexual arousal disorder (FASD) is the recurrent inability to attain sexual activity, or maintain it till completion, e.g., adequate lubrication, expansion/ swelling of the external genitals.
The study included 50 women diagnosed with female sexual dysfunction, which included hypoactive sexual desire disorder, female
sexual arousal disorder, female orgasmic disorder, or combined genital and subjective arousal disorder.
Instead, it lists female sexual interest/ arousal disorder [FSIAD], which "combines features of HSDD and another condition from the DSM-IV known as female
sexual arousal disorder," the FDA pointed out.)
Sexual arousal disorder. The desire for sex might be intact, but there is difficulty or an inability to become aroused or maintain arousal during sexual activity.